All In Biotech

Drug Trial Radar · NCT05205200

Immune Therapy in HR-positive/HER2-negative Metastatic Breast Cancer(ENIGMA)-BCTOP-L-M02

Immune Therapy in HR-positive/HER2-negative Metastatic Breast Cancer

Last checked: Nov 19, 2026Latest source record: Feb 8, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 338 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

338

Planned (sponsor's estimate)

Start

Jun 6, 2022

Primary completion

Feb 1, 2025

Study completion Aug 1, 2026

Sponsor

Lead sponsor
Fudan UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Peking University Cancer Hospital & Institute; First Hospital of China Medical University; Sun Yat-sen University; First Affiliated Hospital Xi'an Jiaotong University; Liaoning Cancer Hospital & Institute; Chongqing University Cancer Hospital; Northern Jiangsu People's Hospital; Fujian Medical University Union Hospital; Ningbo Medical Center Lihuili Hospital; Shanghai First Maternity and Infant Hospital; Shanghai 6th People's Hospital; Affiliated Hospital of Nantong University
First posted
Jan 25, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a prospective, open-label, phase II clinical study for patients with HR+/HER2- advanced breast cancer.

Conditions

  • Breast Cancer
  • Metastatic Cancer

Interventions

  • SHR-1316Drug

    PD-L1 antibody

  • SHR6390Drug

    CDK4/6 inhibitor

  • Nab paclitaxelDrug

    Albumin bound paclitaxel

  • SERDDrug

    Fulvestrant

  • AIDrug

    aromatase inhibitor

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PFSTime frame: Randomization until the first occurrence of disease progression or death from any cause, which ever occurs first, through the end of study (approximately 5 years)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fudan University Shanghai cancer center

    Shanghai, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.